Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Pepcid · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Famotidine | EXPERIMENTAL | Famotidine tablets 40 mg of Dr. Reddy's |
| Pepcid | ACTIVE_COMPARATOR | Pepcid 40 mg Tablets of Merck \& Co., |
| Name | Type | Description |
|---|---|---|
| Famotidine | DRUG | Famotidine Tablets 40 mg |
| Pepcid | DRUG | 40mg tablets |
Inclusion Criteria: Exclusion Criteria: History or presence of significant: • cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic or psychiatric disease. In addition, history or presence of: * alcoholism or drug abuse within...
Pepcid is a small molecule drug being studied in healthy volunteers. It is currently in Phase 1 clinical development. The drug is being investigated for its bioavailability under fasting conditions.
Pepcid is being developed by Dr. Reddy's Laboratories Ltd, a pharmaceutical company listed on the stock exchange under the ticker RDY. The company is conducting clinical trials to evaluate the drug's properties.
Pepcid is in Phase 1 clinical development. It has completed one Phase 1 trial, which was a bioavailability study. The drug is investigational and has not yet been approved for any medical use.
Pepcid has one completed clinical trial, NCT01511731, titled "Bioavailability Study of Famotidine Tablets 40 mg Under Fasting Conditions." This Phase 1 study enrolled 30 healthy male participants in Canada and was active-controlled.
Pepcid is being studied as famotidine tablets. The completed clinical trial NCT01511731 evaluated famotidine tablets at a 40 mg dose. The drug is a small molecule and is being tested in healthy volunteers.